← All indications
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.
Subtype terms (1)
More specific conditions that are subtypes of Prostatic Neoplasms in the MeSH hierarchy.
- Prostatic Neoplasms, Castration-Resistant
419 drugs (157 approved, 262 experimental)
Drugs by status
Approved for this indication (38)
- abiraterone
- histrelin
- sipuleucel-t
- fosfestrol sodium
- dutasteride
- enzalutamide
- sulforaphane
- flutamide
- choline c11
- polyestradiol
- nilutamide
- degarelix acetate
- Ga 68 PSMA-11
- lutetium (177Lu) vipivotide tetraxetan
- radium-223
- cabazitaxel
- piflufolastat
- abarelix
- Fluciclovine
- relugolix
- isopropyl alcohol
- tamsulosin
- triptorelin
- goserelin
- Cyproterone
- capromab pendetide
- zoledronic acid
- Flotufolastat
- estramustine
- padeliporfin
- +8 more
Phase 4 trials (76)
- pivmecillinam
- human factor ix complex (prothrombin complex concentrate)
- nitrous oxide
- angelica
- urea
- saw palmetto
- fesoterodine
- prednisone
- testosterone
- pasireotide
- polyethylene glycol
- docetaxel
- hyaluronic acid
- mepivacaine
- ciprofloxacin
- ibuprofen
- sugammadex
- sodium chloride
- lidocaine
- cellulose
- ertapenem
- silodosin
- indocyanine green
- prilocaine
- trimethoprim
- aminophenazone cyclamate
- semaglutide
- hydroxyethyl starch
- ketamine
- hypromelloses
- +46 more
Phase 3 trials (152)
- methotrexate
- deuterated enzalutamide
- calcium
- inr101
- tadalafil
- desvenlafaxine
- qlg1080
- methylphenidate
- pentoxifylline
- pertuzumab
- prinomastat
- oxaliplatin
- calcitriol
- mk-5684
- florastamin
- calcium citrate
- tasquinimod
- zibotentan
- warfarin
- gvax prostate cancer vaccine
- lycopene
- pf-06821497
- atorvastatin
- aflibercept
- n0728
- 68ga-rm2
- alfuzosin
- lenalidomide
- tamoxifen
- trastuzumab
- +122 more
Phase 2 trials (557)
- poly-iclc
- epirubicin
- mk-1775
- ferumoxytol
- dobutamine
- gozetotide
- ibrutinib
- dkn-01
- psilocybin
- gpi 1485
- verteporfin
- hydroxychloroquine
- acetylcarnitine
- tislelizumab
- bortezomib
- bavituximab
- sepantronium
- tisotumab vedotin
- raloxifene
- sagopilone
- gpc3 car-t cell
- dolastatin
- pvaxrcpsav53l
- panitumumab
- 89zr df-iab2m
- dc1 vaccine
- l-glutamine
- pomegranate
- urolithin a
- larotrectinib
- +527 more
Phase 1 trials (294)
- rspsma protein
- tucotuzumab celmoleukin
- ino-5150
- qs-21
- ktx-2001
- gm-ct-01
- 68ga-labeled ny108
- etbx-071
- azd8186
- imiquimod
- dabigatran
- clarithromycin
- v935
- lisinopril
- tris-poc
- pti-122
- cea gene modified t cells
- naptumomab estafenatox
- ga-oncoacp3
- mocetinostat
- etbx-051
- vistusertib
- sgi-1776
- cart-psma-tgfbetardn cells
- creatine
- ny-eso-1 peptides
- bay2010112
- sasanlimab
- gpi-0100
- dribbles
- +264 more
Other trials (59)
- 124i-psca
- formalin
- [68ga]ga-htk03149
- estrogen
- indole-3-carbinol
- magnesium sulfate
- gadodiamide
- 41 ca
- [18f]f-resca-t4
- zenocutuzumab
- euflavine
- sarcosine
- tc-99m
- F 18-fluoroazomycin arabinoside
- odyliresin
- ykl-40 peptide
- pravastatin
- remifentanil
- omega-3 fatty acids
- egfrviii peptide
- ranolazine
- multivitamins
- whey protein
- platelet-rich plasma
- her2/neu peptide
- mdx1201-a488
- ga-nota-rt4
- c11 methionine
- quinestrol
- tempol
- +29 more
Organizations
Organization Involved with Phase 4 Indications (50)
- Canadian Urology Research Consortium
- Tel Aviv University
- Ipsen
- Finnish Prostate Cancer Group
- University of Ottawa
- AstraZeneca
- Procter and Gamble
- Pennsylvania State University
- Sanofi
- Yonsei University
- Wonju Christian Hospital
- University of Western Ontario
- University of Connecticut
- Radboud University
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of Brescia
- University of Toronto
- University of London
- Northwestern University
- Bay State Clinical Trials, Inc.
- Sanofi-Synthelabo
- National Cancer Institute (NCI)
- Eulji University
- Chesapeake Urology Research Associates
- George Washington University
- Bayer
- Vanderbilt University
- San Bernfardino Urological Associates
- University of Angers
- Sun Yat-Sen University
- +20 more
Organization Involved with Phase 3 Indications (291)
- University of Wisconsin
- Seattle Prostate Institute
- Orebro University
- GPC Biotech Inc.
- Fondazione Giovanni Pascale
- Bristol-Myers Squibb
- Newcastle University
- Maastricht University
- New York Prostate Institute
- Cancer Trials Ireland
- Oakwood Laboratories, LLC
- CMX Research
- Maitland Cancer Appeal
- Radiation Therapy Oncology Group
- Stanford University
- University of Oxford
- Southwest Oncology Group
- UNICANCER
- University of Pittsburgh
- University of Seville
- Millennium Pharmaceuticals
- Regeneron
- Foundation Medicine
- University of L'Aquila
- Canadian Cancer Trials Group
- Hospital Universitario Lucus Augusti
- Active Biotech AB
- Scandinavian Prostate Cancer Group
- Universidad de Cordoba
- Academic and Community Cancer Research United
- +261 more
Organization Involved with Phase 2 Indications (411)
- Kaiser Permanente
- Pepscan Therapeutics
- CureVac AG
- Australian Nuclear Science and Technology Organisation
- City of Hope National Medical Center
- National Institute on Aging (NIA)
- Radio Isotope Therapy of America
- Prostate Cancer Clinical Trials Consortium
- Illinois CancerCare, P.C.
- Providence Health & Services
- Central European Society for Anticancer Drug Research (CESAR)
- National Comprehensive Cancer Network
- Singapore General Hospital
- ImaginAb, Inc.
- University of Erlangen-Nuremberg
- Aga Khan University
- James Graham Brown Cancer Center
- Rhode Island Hospital
- Hospital Moinhos de Vento
- St. Petersburg State Public Medical Institution
- Progen Pharmaceuticals
- Ospedale Beata Vergine
- Jinan University
- North Middlesex University Hospital NHS Trust
- Italian Trial in Medical Oncology
- University of Central Florida
- Cognis
- University of Quebec
- Advanced Accelerator Applications
- Alexandra Hospital, Athens, Greece
- +381 more
Organization Involved with Phase 1 Indications (120)
- Stand Up To Cancer
- Impact Therapeutics, Inc.
- Northern Sydney Local Health District
- Frederikssund Hospital
- Viralytics
- Ambrilia Biopharma, Inc.
- Five Eleven Pharma, Inc.
- Monash University
- Cancer Targeted Technology
- Prostate Oncology Specialists, Inc.
- Asana BioSciences
- National Center for Research Resources (NCRR)
- Invicro
- University of Queensland
- Nektar Therapeutics
- Pacific Coast Imaging
- Inovio Pharmaceuticals
- University of Tuebingen
- The Parker Institute
- Allife Medical Science and Technology Co., Ltd.
- Bastyr University
- MorphoSys
- University of Cincinnati
- Polaris Group
- Verastem, Inc.
- CytoVac A/S
- EDAP TMS S.A.
- Placon Therapeutics
- Intuitive Surgical
- Clinical Research Services Turku
- +90 more
Organization Involved with Other Experimental Indications (37)
- Martini-Klinik am UKE GmbH
- Norwegian School of Sport Sciences
- Matrix Biomed, Inc.
- Peking University
- Medical Research Foundation, Oregon
- Hualien Tzu Chi General Hospital
- University of Zurich
- University of Leeds
- Hospital de Transplante Doutor Euryclides de Jesus Zerbini
- Quadram Institute
- Nikkei (Canada) Marketing Limited
- Lee's Pharmaceutical
- University of East Anglia
- Urology of Virginia
- Lotte & John Hecht Memorial Foundation
- Wageningen University
- Government of Hong Kong
- Jagiellonian University
- University of California, Berkeley
- Swedish Cancer Foundation
- Vancouver Coastal Health
- Oregon State University
- Florida Urology Associates
- Radioterapia Oncologica AOUC
- Chang Gung University
- Oslo Metropolitan University
- Ospedale S. Giovanni Bellinzona
- World Cancer Research Fund International
- Quercegen Pharmaceuticals
- Kagawa University
- +7 more